JP4831965B2 - ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造 - Google Patents

ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造 Download PDF

Info

Publication number
JP4831965B2
JP4831965B2 JP2004510760A JP2004510760A JP4831965B2 JP 4831965 B2 JP4831965 B2 JP 4831965B2 JP 2004510760 A JP2004510760 A JP 2004510760A JP 2004510760 A JP2004510760 A JP 2004510760A JP 4831965 B2 JP4831965 B2 JP 4831965B2
Authority
JP
Japan
Prior art keywords
statin
composition
less
particles
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004510760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532352A (ja
JP2005532352A5 (enExample
Inventor
クーパー，ユージーン，アール．
ホーヴェイ，ダグラス
キャリー，グレタ
リンドナー，マリー
リヴァーシッジ，エレーン
リヴァーシッジ，ゲイリー，ジー．
ライド，トゥウラ
Original Assignee
エラン ファーマ インターナショナル，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン ファーマ インターナショナル，リミティド filed Critical エラン ファーマ インターナショナル，リミティド
Publication of JP2005532352A publication Critical patent/JP2005532352A/ja
Publication of JP2005532352A5 publication Critical patent/JP2005532352A5/ja
Application granted granted Critical
Publication of JP4831965B2 publication Critical patent/JP4831965B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004510760A 2002-06-10 2003-06-10 ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造 Expired - Fee Related JP4831965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38740402P 2002-06-10 2002-06-10
US60/387,404 2002-06-10
PCT/US2003/016206 WO2003103640A1 (en) 2002-06-10 2003-06-10 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2005532352A JP2005532352A (ja) 2005-10-27
JP2005532352A5 JP2005532352A5 (enExample) 2010-08-05
JP4831965B2 true JP4831965B2 (ja) 2011-12-07

Family

ID=29736310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510760A Expired - Fee Related JP4831965B2 (ja) 2002-06-10 2003-06-10 ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造

Country Status (5)

Country Link
EP (1) EP1531799A1 (enExample)
JP (1) JP4831965B2 (enExample)
AU (1) AU2003245313A1 (enExample)
CA (1) CA2488499C (enExample)
WO (1) WO2003103640A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
DE10339354A1 (de) * 2003-08-27 2005-04-07 Beisel, Günther Mittel zur Behandlung des metabolischen Syndroms
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20130103818A (ko) 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
KR101389061B1 (ko) 2004-03-29 2014-04-28 와이어쓰 엘엘씨 종합비타민 및 무기물 영양 보충제
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
EP1871345B1 (en) 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
US20090227610A1 (en) * 2005-06-08 2009-09-10 Kowa Company, Ltd. Novel triglyceride reducing agent
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
JP5113527B2 (ja) * 2005-11-11 2013-01-09 持田製薬株式会社 ゼリー組成物
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
AU2007223981B2 (en) * 2006-03-07 2011-12-01 Osteoscreen Ip, Llc HMG Co-A reductase inhibitor enhancement of bone and cartilage
PL2018153T3 (pl) 2006-04-26 2012-09-28 Rosemont Pharmaceuticals Ltd Ciekłe kompozycje doustne
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008026702A1 (fr) * 2006-08-30 2008-03-06 Kyushu University, National University Corporation Composition pharmaceutique contenant une nanoparticule de statine encapsulée
ES2425969T3 (es) * 2007-04-27 2013-10-18 Kyushu University, National University Corporation Agente para el tratamiento de enfermedades pulmonares
ES2731881T3 (es) 2007-09-25 2019-11-19 Formulex Pharma Innovations Ltd Composiciones que comprenden compuestos activos lipófilos y método para su preparación
FR2937537A1 (fr) * 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
ITFI20120268A1 (it) * 2012-12-03 2014-06-04 Diopeite Consulting Ltd Composizioni farmaceutiche per il trattamento dell'obesita'
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
ES2995737T3 (en) 2015-01-06 2025-02-11 Arena Pharm Inc Compound for use in treating conditions related to the s1p1 receptor
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2019143981A1 (en) * 2018-01-19 2019-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
EP3801459B1 (en) 2018-06-06 2024-08-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH04321680A (ja) * 1990-10-15 1992-11-11 Merck & Co Inc クロノスタキス・コンパクチウスクラから得た酵素を使用した、ロバスタチン酸の酵素加水分解による６（Ｒ）−〔２−（８（Ｓ）−ヒドロキシ−２（Ｓ），６（Ｒ）−ジメチル−１，２，６，７，８，８ａ（Ｒ）−ヘキサヒドロナフチル）−エチル〕−４（Ｒ）−ヒドロキシ−３，４，５，６−テトラヒドロ−２Ｈ−ピラン−２−オン・トリオール酸の生合成的製造方法
JPH07165562A (ja) * 1992-07-01 1995-06-27 Sterling Winthrop Inc 表面を修飾された抗癌性ナノ粒子
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
WO1999065469A2 (en) * 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
JP2001509518A (ja) * 1997-07-09 2001-07-24 エラン ファーマシューティカル テクノロジーズ セルロース系表面安定剤を用いたヒト免疫不全ウイルス（ｈｉｖ）プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法
WO2001078680A2 (en) * 2000-04-13 2001-10-25 Novartis Ag Pharmaceutical compositions comprising fluvastatin
JP2002536405A (ja) * 1999-02-11 2002-10-29 イーデンランド、インコーポレイテッド ウイルス感染症の治療方法
JP2004523552A (ja) * 2001-02-22 2004-08-05 スカイファーマ・カナダ・インコーポレーテッド 低減した摂食−絶食効果を伴うフィブラート−スタチンの組合わせ
JP2005529911A (ja) * 2002-05-06 2005-10-06 エラン ファーマ インターナショナル，リミティド ナノ粒子ナイスタチン製剤
JP2005531606A (ja) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118517C (en) * 1992-06-10 2003-10-14 Gary G. Liversidge Surface modified nsaid nanoparticles
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
EP1322289B1 (en) * 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate
JP2004509146A (ja) * 2000-09-20 2004-03-25 スカイファーマ・カナダ・インコーポレーテッド 安定化フィブレート微粒子
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04321680A (ja) * 1990-10-15 1992-11-11 Merck & Co Inc クロノスタキス・コンパクチウスクラから得た酵素を使用した、ロバスタチン酸の酵素加水分解による６（Ｒ）−〔２−（８（Ｓ）−ヒドロキシ−２（Ｓ），６（Ｒ）−ジメチル−１，２，６，７，８，８ａ（Ｒ）−ヘキサヒドロナフチル）−エチル〕−４（Ｒ）−ヒドロキシ−３，４，５，６−テトラヒドロ−２Ｈ−ピラン−２−オン・トリオール酸の生合成的製造方法
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH07165562A (ja) * 1992-07-01 1995-06-27 Sterling Winthrop Inc 表面を修飾された抗癌性ナノ粒子
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
JP2001509518A (ja) * 1997-07-09 2001-07-24 エラン ファーマシューティカル テクノロジーズ セルロース系表面安定剤を用いたヒト免疫不全ウイルス（ｈｉｖ）プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法
WO1999065469A2 (en) * 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
JP2002536405A (ja) * 1999-02-11 2002-10-29 イーデンランド、インコーポレイテッド ウイルス感染症の治療方法
WO2001078680A2 (en) * 2000-04-13 2001-10-25 Novartis Ag Pharmaceutical compositions comprising fluvastatin
JP2004523552A (ja) * 2001-02-22 2004-08-05 スカイファーマ・カナダ・インコーポレーテッド 低減した摂食−絶食効果を伴うフィブラート−スタチンの組合わせ
JP2005529911A (ja) * 2002-05-06 2005-10-06 エラン ファーマ インターナショナル，リミティド ナノ粒子ナイスタチン製剤
JP2005531606A (ja) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ

Also Published As

Publication number Publication date
JP2005532352A (ja) 2005-10-27
AU2003245313A1 (en) 2003-12-22
CA2488499A1 (en) 2003-12-18
WO2003103640A1 (en) 2003-12-18
CA2488499C (en) 2013-03-19
EP1531799A1 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
JP4831965B2 (ja) ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
JP4533134B2 (ja) ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
JP4395074B2 (ja) ナノ粒子状フィブラート製剤
US7927627B2 (en) Nanoparticulate fibrate formulations
US20110027371A1 (en) Nanoparticulate statin formulations and novel statin combinations
US20040033202A1 (en) Nanoparticulate sterol formulations and novel sterol combinations
JP2006508105A5 (enExample)
US20080213378A1 (en) Nanoparticulate statin formulations and novel statin combinations
ZA200410209B (en) Nanoparticulate fibrate formulations
HK1146231A (en) Nanoparticulate fibrate formulations
HK1146232A (en) Nanoparticulate fibrate formulations
NO346970B1 (no) Nanopartikulære fiberformuleringer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061122

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061122

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20061122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100601

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110621

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110825

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110920

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140930

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees